PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2013.28.4.2622013284262Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes MellitusYoung Min Cho, Rhonda D. Wideman, Timothy J. Kiefferhttps://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2013.28.4.262, https://synapse.koreamed.org/pdf/10.3803/EnM.2013.28.4.262, http://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2013.28.4.262
Clinical Therapeutics10.1016/j.clinthera.2015.01.0032015373483-493Emerging New Therapies for the Treatment of Type 2 Diabetes Mellitus: Glucagon-like Peptide-1 Receptor AgonistsChristopher A. Lindamood, James R. Taylorhttps://api.elsevier.com/content/article/PII:S0149291815000120?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0149291815000120?httpAccept=text/plain
Diabetes mellitus10.14341/dm88042017204286-298Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetesGagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovichhttps://dia-endojournals.ru/dia/article/viewFile/8804/6915, https://dia-endojournals.ru/dia/article/viewFile/8804/6915
The Journal of Korean Diabetes10.4093/jkd.2018.19.1.35201819135Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes AssociationHyun Jin Kimhttps://synapse.koreamed.org/pdf/10.4093/jkd.2018.19.1.35, https://synapse.koreamed.org/DOIx.php?id=10.4093/jkd.2018.19.1.35, https://e-jkd.org/DOIx.php?id=10.4093/jkd.2018.19.1.35
Clinical Therapeutics10.1016/j.clinthera.2017.03.01320173961244-1264Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor AgonistsQiuhe Jihttps://api.elsevier.com/content/article/PII:S0149291817301959?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0149291817301959?httpAccept=text/plain
Diabetes mellitus10.14341/dm96232018214293-300Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetesNina A. Petunina, Milena Е. Telnovahttps://dia-endojournals.ru/dia/article/viewFile/9623/7382, https://dia-endojournals.ru/dia/article/viewFile/9623/7382
Diabetes Research and Clinical Practice10.1016/j.diabres.2019.01.033201914978-88Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative reviewLuba Yammine, Thomas R. Kosten, Maria Pimenova, Joy M. Schmitzhttps://api.elsevier.com/content/article/PII:S0168822718317339?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168822718317339?httpAccept=text/plain
10.21203/rs.2.16671/v32020Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trialsJing Qin, Li Songhttps://www.researchsquare.com/article/rs-7309/v3, https://www.researchsquare.com/article/rs-7309/v3.html
10.21203/rs.2.16671/v12019Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trialsJing Qin, Li Songhttps://www.researchsquare.com/article/rs-7309/v1, https://www.researchsquare.com/article/rs-7309/v1.html
10.21203/rs.2.16671/v22019Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trialsJing Qin, Li Songhttps://www.researchsquare.com/article/rs-7309/v2, https://www.researchsquare.com/article/rs-7309/v2.html